Technical Analysis for TVGN - Tevogen Bio Holdings Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
NR7 | Range Contraction | 4.41% | |
NR7-2 | Range Contraction | 4.41% | |
Narrow Range Bar | Range Contraction | 4.41% | |
Wide Bands | Range Expansion | 4.41% | |
NR7 | Range Contraction | 6.77% | |
NR7-2 | Range Contraction | 6.77% | |
Narrow Range Bar | Range Contraction | 6.77% |
Alert | Time |
---|---|
Gapped Up (Full) | about 22 hours ago |
Rose Above Previous Day's High | about 22 hours ago |
Rose Above 10 DMA | about 22 hours ago |
2x Volume Pace | about 22 hours ago |
1.5x Volume Pace | about 22 hours ago |
Get a Trading Assistant
- Earnings date: Unknown
Tevogen Bio Holdings Inc. Description
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and twelve pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Artificial Intelligence Immunotherapy Infectious Diseases Virotherapy Drug Development Neurological Disorders
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.09 |
52 Week Low | 0.2578 |
Average Volume | 20,087,270 |
200-Day Moving Average | 1.98 |
50-Day Moving Average | 1.17 |
20-Day Moving Average | 1.89 |
10-Day Moving Average | 1.45 |
Average True Range | 0.36 |
RSI (14) | 47.64 |
ADX | 30.7 |
+DI | 29.75 |
-DI | 20.99 |
Chandelier Exit (Long, 3 ATRs) | 2.02 |
Chandelier Exit (Short, 3 ATRs) | 2.08 |
Upper Bollinger Bands | 3.05 |
Lower Bollinger Band | 0.73 |
Percent B (%b) | 0.3 |
BandWidth | 123.06 |
MACD Line | 0.01 |
MACD Signal Line | 0.11 |
MACD Histogram | -0.0995 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.96 | ||||
Resistance 3 (R3) | 2.01 | 1.89 | 1.87 | ||
Resistance 2 (R2) | 1.89 | 1.75 | 1.86 | 1.84 | |
Resistance 1 (R1) | 1.65 | 1.66 | 1.59 | 1.60 | 1.81 |
Pivot Point | 1.53 | 1.53 | 1.50 | 1.50 | 1.53 |
Support 1 (S1) | 1.29 | 1.39 | 1.23 | 1.24 | 1.03 |
Support 2 (S2) | 1.17 | 1.30 | 1.14 | 1.00 | |
Support 3 (S3) | 0.93 | 1.17 | 0.97 | ||
Support 4 (S4) | 0.88 |